Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2015

01.01.2015

Solvent/detergent plasma: pharmaceutical characteristics and clinical experience

verfasst von: Giancarlo Maria Liumbruno, Massimo Franchini

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

The solvent/detergent treatment is an established virus inactivation technology that has been industrially applied for manufacturing plasma derived medicinal products for almost 30 years. Solvent/detergent plasma is a pharmaceutical product with standardised content of clotting factors, devoid of antibodies implicated in transfusion-related acute lung injury pathogenesis, and with a very high level of decontamination from transfusion-transmissible infectious agents. Many clinical studies have confirmed its safety and efficacy in the setting of congenital as well as acquired bleeding disorders. This narrative review will focus on the pharmaceutical characteristics of solvent/detergent plasma and the clinical experience with this blood product.
Literatur
1.
Horowitz B, Wiebe ME, Lippin A, Stryer MH (1985) Inactivation of viruses in labile blood derivatives: disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 25:516–522PubMedCrossRef
2.
Prince AM, Horowitz B, Brotman B (1986) Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1:706–710PubMedCrossRef
3.
Dichtelmüller HO, Biesert L, Fabbrizzi F et al (2009) Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Therapeutics Association member companies. Transfusion 49:1931–1943PubMedCrossRef
4.
Neurath AR, Vernon SK, Dobkin MB, Rubin BA (1972) Characterization of subviral components resulting from treatment of rabies virus with tri(n-buty1)phosphate. J Gen Virol 14:33–48PubMedCrossRef
5.
Omenn GS (2011) Data management and data integration in the HUPO plasma proteome project. Methods Mol Biol 696:247–257PubMedCrossRef
6.
7.
Hellstern P, Sachse H, Schwinn H, Oberfrank K (1992) Manufacture and in vitro characterization of solvent/detergent-treated plasma. Vox Sang 63:178–185PubMedCrossRef
8.
Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW (1992) Solvent/detergent-treated plasma. A virus-inactivated substitute for fresh frozen plasma. Blood 79:826–833PubMed
9.
Biesert L, Shartono H (1998) Solvent/detergent treatment of human plasma: a very robust method for virus inactivation. Validation of virus safety of Octaplas. Vox Sang 74(Suppl 1):207–212PubMedCrossRef
10.
Prowse C (2009) Properties of pathogen-inactivated plasma components. Transfus Med Rev 23:124–133PubMedCrossRef
11.
Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM) (2007) 07/2008:1646. Human plasma (pooled and treated for virus inactivation). Plasma humanum coagmentatum conditumque ad exstinguendum virum. In: Council of Europe (ed) European Pharmacopoeia, Supplement 6.2, 6th edn. Council of Europe, Strasbourg Cedex, France, p 3760–3762. http://​gendocs.​ru/​docs/​5/​4959/​conv_​1/​file1.​pdf. Accessed 15 March 2014
12.
Pelletier JP, Transue S, Snyder EL (2006) Pathogen inactivation techniques. Best Pract Res Clin Haematol 19:205–242PubMedCrossRef
13.
Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M (2006) A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable bag system. Transfusion 46:2100–2108PubMedCrossRef
14.
El-Ekiaby M, Sayed MA, Caron C et al (2010) Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 20:48–61PubMedCrossRef
15.
Jilma-Stohlawetz P, Kursten FW, Horvath M et al (2013) Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion 53:1906–1917PubMedCrossRef
16.
Heger A, Svae TE, Neisser-Svae A, Jordan S, Behizad M, Römisch J (2009) Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 97:219–225PubMedCrossRef
17.
Liumbruno GM, Sodini ML, Grazzini G, Tuscan Transfusion System (2008) Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma. Blood Transfus 6:25–36PubMedCentralPubMed
18.
Koenigbauer UF, Eastlund T, Day JW (2000) Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 40:1203–1206PubMedCrossRef
19.
Liumbruno GM, Catalano L, Piccinini V, Pupella S, Grazzini G (2009) Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components. Blood Transfus 7:86–93PubMedCentralPubMed
20.
Chou ML, Wu YW, Su CY, Lee LW, Burnouf T (2012) Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. Vox Sang 102:277–284PubMedCrossRef
21.
Sharma AD, Sreeram D, Erb T, Grocott HP (2000) Solvent-detergent fresh frozen plasma. A superior alternative to standard fresh frozen plasma? J Cardiothorac Vasc Anesth 14:712–717PubMedCrossRef
22.
Hellstern P (2004) Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11:346–350PubMedCrossRef
23.
Solheim BG, Seghatchian J (2006) Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 35:83–90PubMedCrossRef
24.
Piquet Y, Janvier G, Selosse P et al (1992) Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63:251–256PubMedCrossRef
25.
Sinnott P, Bodger S, Gupta A, Brophy M (2004) Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet 31:271–274PubMedCrossRef
26.
Sachs UJ, Kauschat D, Bein G (2005) White blood cell reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 45:1628–1631PubMedCrossRef
27.
Flesland O, Seghatchian J, Solheim BG (2003) The Norwegian Plasma Fractionation Project: a 12-year clinical and economic success story. Transfus Apher Sci 28:93–100PubMedCrossRef
28.
Steinsvåg CT, Espinosa A, Flesland O (2013) Eight years with haemovigilance in Norway. What have we learnt? Transfus Apher Sci 49:548–552PubMedCrossRef
29.
Thevis M, Krug O, Geyer H et al (2013) Monitoring drug residues in donor blood/plasma samples using LC-(MS)/MS: a pilot study. Drug Test Anal 5:380–383PubMedCrossRef
30.
31.
Feys HB, Van Aelst B, Devreese K et al (2014) Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 106:307–315PubMedCrossRef
32.
Seltsam A, Müller TH (2013) Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 162:442–454PubMedCrossRef
33.
Grazzini G, Rossi G, Rafanelli D et al (2008) Quality control of recovered plasma for fractionation: an extensive Italian study. Transfusion 48:1459–1468PubMedCrossRef
34.
Heger A, Kannicht C, Römisch J, Svae TE (2007) Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 92:206–212PubMedCrossRef
35.
de Jonge J, Groenland THN, Metselaar HJ et al (2002) Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®). Anesth Analg 94:1127–1131PubMedCrossRef
36.
Solheim BG, Bergan A, Brosstad F, Innes R, Svennevig JL (2003) Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP/Octaplas). Anesth Analg 96:1230–1231 author reply 1231–1232PubMedCrossRef
37.
Beeck H, Hellstern P (1998) In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74(Suppl 1):219–223PubMedCrossRef
38.
Magner JJ, Crowley KJ, Boylan JF (2007) Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 21:410–413PubMedCrossRef
39.
Sandler SG (2007) It is time to bring back solvent-detergent plasma. Curr Opin Hematol 14:640–641PubMedCrossRef
40.
Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M (2006) Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 16:266–275PubMedCrossRef
41.
Thiéry G, Jacobs F, Bussel A et al (2004) Acute hyperphosphatemia after plasma exchange with S/D-treated plasma. Transfusion 44:947–948PubMedCrossRef
42.
Flamholz R, Jeon HR, Baron JM, Baron BW (2000) Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 15:169–172PubMedCrossRef
43.
Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121:778–785PubMedCrossRef
44.
Rizvi MA, Vesely JN, George JN et al (2000) Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura–haemolytic–uremic syndrome. Transfusion 40:896–901PubMedCrossRef
45.
McMinn JR Jr, Thomas IA, Terrel DR, Duvall D, Vesely SK, George JN (2003) Complications of plasma exchange in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 43:415–416PubMedCrossRef
46.
Rock G (2011) A comparison of methods of pathogen inactivation of FFP. Vox Sang 100:169–178PubMedCrossRef
47.
Picker SM (2013) Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus 11:343–348PubMedCentralPubMed
48.
Benjamin RJ, McLaughlin LS (2012) Plasma components: properties, differences, and uses. Transfusion 52(Suppl):9S–19SPubMedCrossRef
49.
Hacquard M, Lecompte T, Belcour B et al (2012) Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang 102:354–361PubMedCrossRef
50.
Singh Y, Sawyer LS, Pinkoski LS et al (2006) Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46:1168–1177PubMedCrossRef
51.
Smith J, Rock G (2010) Protein quality in Mirasol pathogen reduction technology–treated, apheresis-derived fresh-frozen plasma. Transfusion 50:926–931PubMedCrossRef
52.
Zeiler T, Wittmann G, Zimmermann R, Hintz G, Huhn D, Riess H (2000) The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol 111:986–987PubMed
53.
Doyle S, O’Brien P, Murphy K, Fleming C, O’Donnell J (2003) Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 14:283–287PubMed
54.
Aznar JA, Molina R, Montoro JM (1999) Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 39:748–750PubMedCrossRef
55.
Osselaer JC, Debry C, Goffaux M et al (2008) Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 48:108–117PubMedCrossRef
56.
Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ (2004) Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14:39–44PubMedCrossRef
57.
Schlenke P, Hervig T, Isola H et al (2008) Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 48:697–705PubMedCrossRef
58.
Larrea L, Calabuig M, Roldan V et al (2009) The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 41:199–204PubMedCentralPubMedCrossRef
59.
Inbal A, Epstein O, Blickstein D, Kombrot N, Brenner B, Martinowitz U (1993) Evaluation of solvent/detergent treated plasma in the management of patients with acquired coagulation disorders. Blood Coagul Fibrinolysis 4:559–604CrossRef
60.
Horowitz MS, Pehta JC (1998) SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 74(Suppl 1):231–235PubMedCrossRef
61.
Santagostino E, Mancuso ME, Morfini M et al (2006) Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 91:634–639PubMed
62.
Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW (2004) Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 125:69–73PubMedCrossRef
63.
Holland LL, Brooks JP (2006) Toward rational fresh frozen plasma transfusion. Am J Clin Pathol 126:133–139PubMedCrossRef
64.
Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145:24–33PubMedCrossRef
65.
Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party (2011) Recommendations for the transfusion management of patients in the peri-operative period I. The pre-operative period. Blood Transfus 9:19–40PubMedCentralPubMed
66.
Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party (2011) Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period. Blood Transfus 9:189–217PubMedCentralPubMed
67.
Lerner RG, Nelson J, Sorcia E (2000) Evaluation of solvent/detergent treated plasma in patients with a prolonged prothrombin time. Vox Sang 79:161–167PubMedCrossRef
68.
Beck KH, Mortelsmans Y, Kretschmer VV, Höltermann W, Lukasewitz P (2000) Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed 27:144–148PubMed
69.
Williamson LM, Llewelyn CA, Fisher NC et al (1999) A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 39:1227–1234PubMedCrossRef
70.
71.
Solheim BG, Granov DA, Juravlev VA et al (2005) Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 89:19–26PubMedCrossRef
72.
Chekrizova V, Murphy WG (2006) Solvent–detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 16:85–91PubMedCrossRef
73.
Freeman JW, Williamson LM, Llewelyn C et al (1998) A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang 74(Suppl 1):225–229PubMedCrossRef
74.
Bindi ML, Miccoli M, Marietta M et al (2013) Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study. Vox Sang 105:137–143PubMedCrossRef
75.
Lepri D, Capuzzo E, Mattioli AV et al (2013) Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy. Recenti Prog Med 104:106–111PubMed
76.
Haubelt H, Blome M, Kiessling AH et al (2002) Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 82:9–14PubMedCrossRef
77.
78.
Tollofsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG (2003) Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 29:1736–1743PubMedCrossRef
79.
De Silvestro G, Bagatella P, Tison T et al (2007) Virus-inactivated—Plasmasafe: a one-year experience. Blood Transfus 5:134–142PubMedCentralPubMed
80.
McCarthy LJ (2006) The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma. Br J Haematol 133:107PubMed
81.
Scully M, Longair I, Flynn M, Berryman J, Machin SJ (2007) Cryosupernatant and solvent detergent fresh frozen plasma (octaplas) usage in a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 93:154–158PubMedCrossRef
82.
Edel E, Al-Ali HK, Seeger S, Kauschat D, Matthes G (2010) Efficacy and safety profile of solvent/detergent plasma in the treatment of acute thrombotic thrombocytopenic purpura: a single-center experience. Transfus Med Hemother 37:13–19PubMedCentralPubMedCrossRef
83.
Andreu G (2010) France: solvent/detergent plasma. In: AuBuchon JP, Prowse CV (eds) Pathogen inactivation: the penultimate paradigm shift. AABB Press, Bethesda, pp 137–151
84.
Krusius T, Auvinen M-K, Tuimala (2010) Introduction of octaplas in clinical use decreased the rate of serious adverse reactions. Vox Sang 99(Suppl 1):P-1018
85.
Baudoux E, Margraff U, Coenen A et al (1998) Hemovigilance: clinical tolerance of solvent-detergent treated plasma. Vox Sang 74Ssuppl 1):237-239
86.
Bolton-Maggs PH, Cohen H (2013) Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 163:303–314PubMedCentralPubMedCrossRef
87.
88.
Facco G, Pupella S, Piccinini V, Catalano L, Vaglio S (2012) I dati italiani di emovigilanza. Blood Transfus 10(Suppl 1):s57–s58
89.
AuBuchon JP, Birkmeyer JD (1994) Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 272:1210–1214PubMedCrossRef
90.
Pereira A (1999) Cost-effectiveness of transfusing virus inactivated plasma instead of standard plasma. Transfusion 39:479–487PubMedCrossRef
91.
Jakson BR, AuBuchon JP, Birkmeyer JD (1999) Update of cost-effectiveness analysis for solvent-detergent-treated plasma. JAMA 282:329CrossRef
92.
Riedler GF, Haycox AR, Duggan AK, Dakin HA (2003) Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 85:88–95PubMedCrossRef
93.
van Eerd MC, Mario Ouwens JN, de Peuter MA (2010) Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK. Transfus Apher Sci 43:251–259PubMedCrossRef
94.
95.
Huisman EL, van Eerd MC, Ouwens JN, de Peuter MA (2013) Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci. doi:10.​1016/​j.​transci.​2013.​04.​045 PubMed
Metadaten
Titel
Solvent/detergent plasma: pharmaceutical characteristics and clinical experience
verfasst von
Giancarlo Maria Liumbruno
Massimo Franchini
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2015
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-014-1086-1

Weitere Artikel der Ausgabe 1/2015

Journal of Thrombosis and Thrombolysis 1/2015 Zur Ausgabe

Report

Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report

Report

Kimura’s disease associated necrotizing eosinophilic vasculitis presenting with recurrent peripheral arterial occlusive disease: a case report and review of the literature

OriginalPaper

A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample

OriginalPaper

Monitoring of dabigatran therapy using Hemoclot® Thrombin Inhibitor assay in patients with atrial fibrillation

OriginalPaper

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials

OriginalPaper

Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise